KR950000159A - Use of attenuated Pseudomonas aeruginosa CFCPA 30720 for the manufacture of a therapeutic and prophylactic vaccine for Pseudomonas aeruginosa infections - Google Patents

Use of attenuated Pseudomonas aeruginosa CFCPA 30720 for the manufacture of a therapeutic and prophylactic vaccine for Pseudomonas aeruginosa infections Download PDF

Info

Publication number
KR950000159A
KR950000159A KR1019930010276A KR930010276A KR950000159A KR 950000159 A KR950000159 A KR 950000159A KR 1019930010276 A KR1019930010276 A KR 1019930010276A KR 930010276 A KR930010276 A KR 930010276A KR 950000159 A KR950000159 A KR 950000159A
Authority
KR
South Korea
Prior art keywords
pseudomonas aeruginosa
attenuated
purified
cfcpa
agent
Prior art date
Application number
KR1019930010276A
Other languages
Korean (ko)
Other versions
KR970001705B1 (en
Inventor
김현수
박완제
문우상
유왕돈
유리안
노갑수
이남중
김영지
조양제
홍선표
Original Assignee
이종기
제일제당 주식회사
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by 이종기, 제일제당 주식회사 filed Critical 이종기
Priority to KR1019930010276A priority Critical patent/KR970001705B1/en
Publication of KR950000159A publication Critical patent/KR950000159A/en
Application granted granted Critical
Publication of KR970001705B1 publication Critical patent/KR970001705B1/en

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/02—Bacterial antigens
    • A61K39/104—Pseudomonadales, e.g. Pseudomonas
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
    • A61K39/40—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum bacterial
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0019—Injectable compositions; Intramuscular, intravenous, arterial, subcutaneous administration; Compositions to be administered through the skin in an invasive manner
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/48—Preparations in capsules, e.g. of gelatin, of chocolate

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Epidemiology (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Immunology (AREA)
  • Mycology (AREA)
  • Microbiology (AREA)
  • Dermatology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Medicinal Preparation (AREA)
  • Peptides Or Proteins (AREA)

Abstract

본 발명은 피셔―데블린 면역형태에 따라 타입 3의 녹농균을 순수하게 분리하여 반복적으로 순화시킴으로써 약독화시켜 수득되는 신규의 안전한 약독화 녹농균주 CFCPA 30720(KCCM 10031)의 녹농균 감염증 치료제 및 예방용 백신의 제조를 위한 용도에 관한 것이다.The present invention provides a novel safe and attenuated Pseudomonas aeruginosa CFCPA 30720 (KCCM 10031) obtained by attenuating by purely separating and repeatedly purifying Pseudomonas aeruginosa of type 3 according to the Fischer-Deblin immunomorphology of a vaccine for the treatment and prevention of Pseudomonas aeruginosa infections. It relates to a use for the production.

본 발명에서 이용되는 약독화 녹농균주 CFCPA 30720(KCCM 10031)는 독성이 없이 안전하며, 그의 세포벽 단백질 성분도 안전하면서도 우수한 항체 생성능을 나타내고, 또한 이들로부터 구성되는 본 발명에 따르는 녹농균 감염 예방 백신 및 녹농균 감염증 치료제는 피셔 면역형 3뿐 아니라 6의 녹농균주에 대해서도 탁월한 교차방어 능력을 나타낸다.The attenuated Pseudomonas aeruginosa CFCPA 30720 (KCCM 10031) used in the present invention is safe without toxicity, its cell wall protein component is safe and shows excellent antibody production ability, and also comprises a Pseudomonas aeruginosa infection prevention vaccine and Pseudomonas aeruginosa infection according to the present invention. Therapeutic agents show excellent cross-protective ability against Pseudomonas aeruginosa strains as well as Fischer immunotype 3.

Description

녹농균 감염증 치료제 및 예방 백신을 제조하기 위한 약독화 녹농균주 CFCPA 30720의 용도Use of attenuated Pseudomonas aeruginosa CFCPA 30720 for the manufacture of a therapeutic and prophylactic vaccine for Pseudomonas aeruginosa infections

본 내용은 요부공개 건이므로 전문내용을 수록하지 않았음Since this is an open matter, no full text was included.

Claims (9)

피셔 면역형의 타입 1에 해당하는 녹농균주를 순수하게 분리하여 반복적으로 순화시켜 약독화시킨 안전한 약독화 녹농균주 CFCPA 30720(KCCM 10031)로부터 순수하게 분리, 정제하여 순득한 세포벽 단백질을 함유함을 특징으로 하는 녹농균 감염 예방 백신.Fischer immunity type 1 Pseudomonas aeruginosa strains were isolated, purified, purified and purified from the safe, attenuated Pseudomonas aeruginosa strain CFCPA 30720 (KCCM 10031). Pseudomonas aeruginosa infection prevention vaccine. 제 1 항에 있어서, 약독화 녹농균주 CFCPA 30720의 LD50이 2.5×108세포 이상임을 특징으로 하는 녹농균 감염 예방 백신.The vaccine of claim 1, wherein the LD 50 of the attenuated Pseudomonas aeruginosa CFCPA 30720 is 2.5 × 10 8 cells or more. 제 1 항에 있어서, 세포벽 단백질 이외에 추가로 약제학적으로 허용되는 부형제를 함유하는 녹농균 감염 예방 백신.2. The Pseudomonas aeruginosa infection prevention vaccine according to claim 1, further comprising a pharmaceutically acceptable excipient in addition to the cell wall protein. 피셔 면역형의 타입 3에 해당하는 녹농균주를 순수하게 분리하여 반복적으로 순화시켜 약독화시킨 안전한 약독화 녹농균주 CFCPA 30720(KCCM 10031)로부터 분리, 정제된 세포벽 단백질에 의해 유도된 녹농균에 대한 면역글로부린을 유효성분으로 함유함을 특징으로 하는 녹농균 감염증 치료제 조성물.Immunoglobulin against Pseudomonas aeruginosa induced by purified cell wall protein isolated from safe attenuated Pseudomonas aeruginosa CFCPA 30720 (KCCM 10031), which was purified, purified and attenuated by Pseudomonas spp. Pseudomonas aeruginosa infectious agent therapeutic composition comprising as an active ingredient. 제 4 항에 있어서, 약제학적으로 허용되는 담체와 함께 동결건조 제제의 형태로 제형화된 녹농균 감염증 치료제.The agent for treating Pseudomonas aeruginosa infection according to claim 4, formulated in the form of a lyophilized preparation with a pharmaceutically acceptable carrier. 제 5 항에 있어서, 약제학적으로 허용되는 담체가 만니톨, 락토즈, 사카로즈 또는 인체 알부민임을 특징으로 하는 녹농균 감염증 치료제.The agent for treating Pseudomonas aeruginosa infection according to claim 5, wherein the pharmaceutically acceptable carrier is mannitol, lactose, saccharose or human albumin. 제 4 항에 있어서, 약제학적으로 허용되는 담체와 함께 액체 제제로 제형화된 녹농균 감염증 치료제.The agent for treating Pseudomonas aeruginosa infection according to claim 4, formulated in a liquid formulation together with a pharmaceutically acceptable carrier. 제 7 항에 있어서, 약제학적으로 허용되는 담체가 생리식염수, 주사용 증류수, 인산염 완충액 또는 수산화 알루미늄임을 특징으로 하는 녹농균 감염증 치료제.8. The agent for treating Pseudomonas aeruginosa infection according to claim 7, wherein the pharmaceutically acceptable carrier is physiological saline, distilled water for injection, phosphate buffer or aluminum hydroxide. 제 4 항에 있어서, 주사제, 정제, 캅셀제, 점안제, 분무제 또는 연고제의 형태로 제형화된 녹농균 감염증 치료제.The agent for treating Pseudomonas aeruginosa infection according to claim 4, formulated in the form of an injection, tablet, capsule, eye drop, spray or ointment. ※ 참고사항 : 최초출원 내용에 의하여 공개하는 것임.※ Note: The disclosure is based on the initial application.
KR1019930010276A 1993-06-07 1993-06-07 Psedomonas infection preventing vaccines using attenuated pseudomonas cfcpa 30720 KR970001705B1 (en)

Priority Applications (1)

Application Number Priority Date Filing Date Title
KR1019930010276A KR970001705B1 (en) 1993-06-07 1993-06-07 Psedomonas infection preventing vaccines using attenuated pseudomonas cfcpa 30720

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
KR1019930010276A KR970001705B1 (en) 1993-06-07 1993-06-07 Psedomonas infection preventing vaccines using attenuated pseudomonas cfcpa 30720

Publications (2)

Publication Number Publication Date
KR950000159A true KR950000159A (en) 1995-01-03
KR970001705B1 KR970001705B1 (en) 1997-02-14

Family

ID=19356962

Family Applications (1)

Application Number Title Priority Date Filing Date
KR1019930010276A KR970001705B1 (en) 1993-06-07 1993-06-07 Psedomonas infection preventing vaccines using attenuated pseudomonas cfcpa 30720

Country Status (1)

Country Link
KR (1) KR970001705B1 (en)

Also Published As

Publication number Publication date
KR970001705B1 (en) 1997-02-14

Similar Documents

Publication Publication Date Title
RU94041223A (en) Agent for motoneuron disease treatment
CA2293470A1 (en) Benzimidazole derivatives
FR2762843B1 (en) NOVEL CYCLOSPORIN DERIVATIVES, THEIR PREPARATION AND THE PHARMACEUTICAL COMPOSITIONS CONTAINING THEM
EA200000608A1 (en) PREVENTION AND TREATMENT OF AMYLOIDOGENIC DISEASE
IL111674A0 (en) 5,6-Dihydropyrone derivatives and pharmaceutical compositions containing them
ES2070131T3 (en) LOW-TOXICITY PHARMACY-LIPID SYSTEMS.
IL111673A (en) 5,6-Dihydropyrone derivatives and pharmaceutical compositions containing them
AU3453493A (en) Pharmaceutical preparation based on rhamnolipid against dermatological diseases, e.g. papilloma virus infections
WO2002092131A3 (en) Immunogenic conjugates of low molecular weight hyaluronic acid with polypeptide toxins
SE9500418L (en) New attenuated Pseudomonas aerugionos strains
KR950000159A (en) Use of attenuated Pseudomonas aeruginosa CFCPA 30720 for the manufacture of a therapeutic and prophylactic vaccine for Pseudomonas aeruginosa infections
KR950000158A (en) Use of attenuated Pseudomonas aeruginosa CFCPA 20215 for the manufacture of a therapeutic and prophylactic vaccine for Pseudomonas aeruginosa infections
KR950000161A (en) Use of attenuated Pseudomonas aeruginosa CFCPA 50243 for the manufacture of a therapeutic and preventive vaccine for Pseudomonas aeruginosa infections
KR950000157A (en) Use of attenuated Pseudomonas aeruginosa CFCPA 10142 for the manufacture of a therapeutic and prophylactic vaccine for Pseudomonas aeruginosa infections
KR950000162A (en) Use of attenuated Pseudomonas aeruginosa CFCPA 60534 for the manufacture of a therapeutic and preventive vaccine for Pseudomonas aeruginosa infections
AU1085392A (en) Alkyl ether carboxylic acid taurides
KR950000160A (en) Use of attenuated Pseudomonas aeruginosa CFCPA 40057 for the manufacture of a therapeutic and prophylactic vaccine for Pseudomonas aeruginosa infections
KR950000163A (en) Use of attenuated Pseudomonas aeruginosa CFCPA 70018 for the manufacture of a therapeutic and preventive vaccine for Pseudomonas aeruginosa infections
KR960700711A (en) Medicine for treating or preventing cerebrovascular diseases
CA2065889A1 (en) Increasing the choroidal blood flow
KR950000164A (en) Pseudomonas aeruginosa infectious agent and its manufacturing method
Mukerjee et al. Effect of adjuvants on immunization with dengue virus-induced cytotoxic factor
RU94020944A (en) Agent for intranasal influenza prophylaxis
KR970704441A (en) Human Immunodeficiency Virus Protease Inhibitor Combination (HIV Protease Inhibitor Combination)
DK0728001T3 (en) Use of 2-aminopurine derivatives for the treatment and prevention of human herpes virus 6 infections

Legal Events

Date Code Title Description
A201 Request for examination
E902 Notification of reason for refusal
G160 Decision to publish patent application
E701 Decision to grant or registration of patent right
GRNT Written decision to grant
FPAY Annual fee payment

Payment date: 20080626

Year of fee payment: 12

LAPS Lapse due to unpaid annual fee